Health brief
BRCA1 Screening Defect, Mandatory Salt Fortification, and Teva FDA Approval
Israel addresses genetic screening defects and desalinated water mineral loss while Teva expands its US biosimilar portfolio.
Health
Gamidor's BRCA1 testing flaw triggered retesting for 100 patients — exposing quality control gaps in Israel's national genetic screening network.
BackgroundBRCA1 genetic mutations significantly increase lifetime risk for hereditary breast and ovarian cancer among Ashkenazi Jewish populations. Israel maintains universal clinical genetic screening programs to identify hereditary risk early across public health clinics.
- Over 90,000 genetic samples were reviewed across Israeli medical institutes to identify potential test discrepancies, leading health officials to request retests for affected patients.
- Gamidor Diagnostics corrected the manufacturing defect and provided updated testing protocols to clinical laboratories across the country.
- Genetic centers across Israel are contacting affected patients directly to collect fresh samples for complimentary verification.
Health
Israel mandating iodized salt counters severe mineral deficiencies caused by desalinated water — fixing a hidden public health side effect without raising prices.
BackgroundDesalinated water accounts for the majority of Israel's municipal drinking water supply but lacks naturally occurring minerals like iodine and magnesium. Widespread reliance on desalinated water has exacerbated iodine deficiency across the population.
- Table salt must contain 25 to 45 milligrams of iodine per kilogram under the new public health directive, aligning Israeli standards with international health guidelines.
- Mandatory price controls will prevent salt producers from raising consumer retail prices following mandatory fortification, protecting low-income households.
- Specialty gourmet and coarse salts remain exempt from mandatory fortification to preserve consumer market choice while covering common table salt.
Health
Innovalve's clinical trial success validates Sheba's $381M heart device deal — bringing open-chest alternatives closer to international regulatory approval.
BackgroundStructural heart repair traditionally requires invasive open-chest surgery with long recovery periods for elderly patients. Transcatheter technologies allow cardiologists to insert replacement valves through blood vessels under local anesthesia.
- Edwards Lifesciences acquired Innovalve for $381 million to expand its structural heart device portfolio, reinforcing Israel's role in global medical device innovation.
- Clinical trials demonstrated high technical success rates and significant reductions in mitral regurgitation, offering a safer alternative for inoperable patients.
- The procedure utilizes six mechanical arms that secure native tissue inside high-risk surgical patients, eliminating the need for cardiopulmonary bypass.
Health
Teva's FDA win for its Prolia biosimilar accelerates its high-margin biologic pivot — securing new US growth as generic drug competition stiffens.
BackgroundTel Aviv-based Teva has aggressively built out a portfolio of generic biologics to offset expiring drug patents and boost gross margins. FDA biosimilar approvals allow lower-cost alternatives to enter major prescription markets.
- Ponlimsi provides a cost-effective alternative for treating postmenopausal osteoporosis and bone loss, expanding Teva's presence in high-margin biologic treatments.
- US regulators accepted a Biologics License Application for AVT80, targeting gastrointestinal drug Entyvio, setting up a potential commercial launch next year.
- Teva is also advancing an omalizumab biosimilar through European and American regulatory approval pipelines, targeting major respiratory market segments.
Health
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
